España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Glioblastoma
CBD Via Inhalation Possible Treatment For Glioblastoma, New Study Offers Hope For Aggressive Brain Cancer
Kintara Posts VAL-083 Data As Adjuvant Therapy In Newly-Diagnosed GBM Patients
Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication
Kintara Posts VAL-083 Data As Adjuvant Therapy In Newly-Diagnosed GBM Patients
Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication
Cannabis-Based Sativex Mouth Spray To Treat Brain Tumors? Trial Gets Underway In England With Backing From National Health Services And Cancer Charities
Document Security Systems Invests $1M In Vivacitas Oncology
Cannabis-Based Sativex Mouth Spray To Treat Brain Tumors? Trial Gets Underway In England With Backing From National Health Services And Cancer Charities
Document Security Systems Invests $1M In Vivacitas Oncology
Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial
Kintara Stock Soars After Site Activation Update On Glioblastoma Trial
Read More...
Glioblastoma Recent News
Yumanity Therapeutics' Glioblastoma Candidate Shows Efficacy In Animal Studies
Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China
Kazia Therapeutics Ltd (NASDAQ: KZIA) has
DelMar Pharma CEO Sheds Light On Glioblastoma, And How Its Drug Could Help Sen. John McCain
Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha
Novocure's Stock Gains 3% As Anthem Now Covers Optune For Its Members